nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL6—bile duct cancer	0.000468	0.000468	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.000466	0.000466	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—EGFR—bile duct cancer	0.000466	0.000466	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—KRAS—bile duct cancer	0.000464	0.000464	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—IL6—bile duct cancer	0.000463	0.000463	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—IL6—bile duct cancer	0.000463	0.000463	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000463	0.000463	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—KRAS—bile duct cancer	0.000463	0.000463	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—ERBB2—bile duct cancer	0.000462	0.000462	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.000462	0.000462	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—EGFR—bile duct cancer	0.00046	0.00046	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.000457	0.000457	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—HRAS—bile duct cancer	0.000456	0.000456	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—HRAS—bile duct cancer	0.000453	0.000453	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000451	0.000451	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—ERBB2—bile duct cancer	0.000447	0.000447	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—HRAS—bile duct cancer	0.000445	0.000445	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000445	0.000445	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—EGFR—bile duct cancer	0.000444	0.000444	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—KRAS—bile duct cancer	0.000444	0.000444	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—KRAS—bile duct cancer	0.000444	0.000444	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.000444	0.000444	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000443	0.000443	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000442	0.000442	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.000442	0.000442	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—KRAS—bile duct cancer	0.00044	0.00044	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—bile duct cancer	0.00044	0.00044	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL6—bile duct cancer	0.000438	0.000438	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RNF43—bile duct cancer	0.000438	0.000438	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—HRAS—bile duct cancer	0.000437	0.000437	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MET—bile duct cancer	0.000436	0.000436	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.000436	0.000436	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—IL6—bile duct cancer	0.000436	0.000436	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—HRAS—bile duct cancer	0.000435	0.000435	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—KRAS—bile duct cancer	0.000434	0.000434	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—IL6—bile duct cancer	0.000433	0.000433	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—IL6—bile duct cancer	0.000433	0.000433	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000433	0.000433	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—HRAS—bile duct cancer	0.000433	0.000433	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.000433	0.000433	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—HRAS—bile duct cancer	0.000431	0.000431	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.00043	0.00043	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—HRAS—bile duct cancer	0.000429	0.000429	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—HRAS—bile duct cancer	0.000426	0.000426	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.00042	0.00042	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—ERBB2—bile duct cancer	0.000418	0.000418	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000418	0.000418	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—IL6—bile duct cancer	0.000416	0.000416	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000416	0.000416	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000415	0.000415	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—IL6—bile duct cancer	0.000414	0.000414	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—IL6—bile duct cancer	0.000412	0.000412	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—bile duct cancer	0.000411	0.000411	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—IL6—bile duct cancer	0.00041	0.00041	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RNF43—bile duct cancer	0.00041	0.00041	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—HRAS—bile duct cancer	0.000409	0.000409	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MET—bile duct cancer	0.000408	0.000408	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—IL6—bile duct cancer	0.000408	0.000408	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—HRAS—bile duct cancer	0.000407	0.000407	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.000406	0.000406	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.000405	0.000405	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—HRAS—bile duct cancer	0.000405	0.000405	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HRAS—bile duct cancer	0.000403	0.000403	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000403	0.000403	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—HRAS—bile duct cancer	0.000403	0.000403	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—HRAS—bile duct cancer	0.000403	0.000403	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.000402	0.000402	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—HRAS—bile duct cancer	0.000401	0.000401	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—HRAS—bile duct cancer	0.0004	0.0004	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.000396	0.000396	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—HRAS—bile duct cancer	0.000394	0.000394	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000393	0.000393	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—bile duct cancer	0.00039	0.00039	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—bile duct cancer	0.000388	0.000388	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—bile duct cancer	0.000386	0.000386	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000386	0.000386	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—bile duct cancer	0.000386	0.000386	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—bile duct cancer	0.000386	0.000386	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—bile duct cancer	0.000384	0.000384	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MMP9—bile duct cancer	0.000383	0.000383	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—bile duct cancer	0.000383	0.000383	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—NRAS—bile duct cancer	0.000382	0.000382	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—HRAS—bile duct cancer	0.000381	0.000381	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.00038	0.00038	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000379	0.000379	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—bile duct cancer	0.000378	0.000378	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HRAS—bile duct cancer	0.000377	0.000377	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000377	0.000377	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—HRAS—bile duct cancer	0.000377	0.000377	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—NRAS—bile duct cancer	0.000376	0.000376	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—HRAS—bile duct cancer	0.000374	0.000374	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000371	0.000371	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.000371	0.000371	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—HRAS—bile duct cancer	0.000369	0.000369	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP2—bile duct cancer	0.000364	0.000364	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—bile duct cancer	0.000361	0.000361	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—bile duct cancer	0.000361	0.000361	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000361	0.000361	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP9—bile duct cancer	0.000359	0.000359	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—bile duct cancer	0.000358	0.000358	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NRAS—bile duct cancer	0.000357	0.000357	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000357	0.000357	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—bile duct cancer	0.000357	0.000357	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000355	0.000355	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—bile duct cancer	0.000353	0.000353	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NRAS—bile duct cancer	0.000351	0.000351	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.000345	0.000345	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—bile duct cancer	0.000342	0.000342	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000342	0.000342	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP2—bile duct cancer	0.00034	0.00034	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—NRAS—bile duct cancer	0.00034	0.00034	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000334	0.000334	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.00033	0.00033	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—KRAS—bile duct cancer	0.000329	0.000329	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—GNAS—bile duct cancer	0.000327	0.000327	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KRAS—bile duct cancer	0.000323	0.000323	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.000323	0.000323	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—bile duct cancer	0.00032	0.00032	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.00032	0.00032	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ERBB2—bile duct cancer	0.000319	0.000319	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—NRAS—bile duct cancer	0.000318	0.000318	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—bile duct cancer	0.00031	0.00031	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.000309	0.000309	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—KRAS—bile duct cancer	0.000308	0.000308	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GNAS—bile duct cancer	0.000306	0.000306	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KRAS—bile duct cancer	0.000302	0.000302	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—ERBB2—bile duct cancer	0.000298	0.000298	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—KRAS—bile duct cancer	0.000293	0.000293	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—bile duct cancer	0.00029	0.00029	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFBR2—bile duct cancer	0.000286	0.000286	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HGF—bile duct cancer	0.000284	0.000284	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ERBB2—bile duct cancer	0.000282	0.000282	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—bile duct cancer	0.000279	0.000279	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—bile duct cancer	0.000275	0.000275	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—KRAS—bile duct cancer	0.000274	0.000274	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP9—bile duct cancer	0.000273	0.000273	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000271	0.000271	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SMAD4—bile duct cancer	0.000271	0.000271	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—bile duct cancer	0.000267	0.000267	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFBR2—bile duct cancer	0.000267	0.000267	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HGF—bile duct cancer	0.000266	0.000266	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB2—bile duct cancer	0.000263	0.000263	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—bile duct cancer	0.000263	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—bile duct cancer	0.000261	0.000261	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—bile duct cancer	0.000257	0.000257	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP9—bile duct cancer	0.000256	0.000256	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SMAD4—bile duct cancer	0.000253	0.000253	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—bile duct cancer	0.00025	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—bile duct cancer	0.000249	0.000249	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—IDH2—bile duct cancer	0.000247	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—bile duct cancer	0.000246	0.000246	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—bile duct cancer	0.000243	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—bile duct cancer	0.000238	0.000238	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—bile duct cancer	0.000233	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—bile duct cancer	0.000227	0.000227	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—bile duct cancer	0.000225	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—bile duct cancer	0.000223	0.000223	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—bile duct cancer	0.000221	0.000221	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—bile duct cancer	0.000214	0.000214	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—IDH1—bile duct cancer	0.000212	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—bile duct cancer	0.000211	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—bile duct cancer	0.000209	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—bile duct cancer	0.000207	0.000207	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS2—bile duct cancer	0.000201	0.000201	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—bile duct cancer	0.0002	0.0002	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFBR2—bile duct cancer	0.0002	0.0002	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—bile duct cancer	0.000195	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—bile duct cancer	0.000195	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GNAS—bile duct cancer	0.000193	0.000193	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SMAD4—bile duct cancer	0.000189	0.000189	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS2—bile duct cancer	0.000188	0.000188	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFBR2—bile duct cancer	0.000187	0.000187	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—bile duct cancer	0.000184	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—bile duct cancer	0.000183	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GNAS—bile duct cancer	0.000181	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—bile duct cancer	0.000177	0.000177	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SMAD4—bile duct cancer	0.000177	0.000177	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—bile duct cancer	0.000173	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—bile duct cancer	0.00017	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—bile duct cancer	0.000166	0.000166	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—bile duct cancer	0.000164	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—bile duct cancer	0.000159	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—bile duct cancer	0.000157	0.000157	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—bile duct cancer	0.000153	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—bile duct cancer	0.000151	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—bile duct cancer	0.00015	0.00015	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—bile duct cancer	0.000148	0.000148	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—bile duct cancer	0.000147	0.000147	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—bile duct cancer	0.000142	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—bile duct cancer	0.00014	0.00014	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—bile duct cancer	0.00014	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—bile duct cancer	0.000139	0.000139	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—bile duct cancer	0.000137	0.000137	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000132	0.000132	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000131	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—bile duct cancer	0.000128	0.000128	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—bile duct cancer	0.000125	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—bile duct cancer	0.000124	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—bile duct cancer	0.000118	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—bile duct cancer	0.000117	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—bile duct cancer	0.000116	0.000116	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—bile duct cancer	0.000115	0.000115	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000114	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—bile duct cancer	0.000114	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—bile duct cancer	0.00011	0.00011	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNAS—bile duct cancer	0.000109	0.000109	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—bile duct cancer	0.000108	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—bile duct cancer	0.000107	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—bile duct cancer	0.000107	0.000107	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—bile duct cancer	0.000106	0.000106	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—bile duct cancer	0.000106	0.000106	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—bile duct cancer	0.000105	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—bile duct cancer	0.0001	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—bile duct cancer	0.0001	0.0001	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—bile duct cancer	9.99e-05	9.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—bile duct cancer	9.92e-05	9.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—bile duct cancer	9.92e-05	9.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—bile duct cancer	9.82e-05	9.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—bile duct cancer	9.56e-05	9.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—bile duct cancer	9.35e-05	9.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—bile duct cancer	9.28e-05	9.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—bile duct cancer	9.13e-05	9.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—bile duct cancer	9.1e-05	9.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—bile duct cancer	8.95e-05	8.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—bile duct cancer	8.74e-05	8.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—bile duct cancer	8.54e-05	8.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—bile duct cancer	8.51e-05	8.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—bile duct cancer	8.43e-05	8.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—bile duct cancer	8.17e-05	8.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—bile duct cancer	8.07e-05	8.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—bile duct cancer	8.07e-05	8.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—bile duct cancer	7.89e-05	7.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—bile duct cancer	7.55e-05	7.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—bile duct cancer	7.55e-05	7.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	7.51e-05	7.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—bile duct cancer	7.5e-05	7.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—bile duct cancer	7.35e-05	7.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—bile duct cancer	7.01e-05	7.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—bile duct cancer	6.94e-05	6.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—bile duct cancer	6.88e-05	6.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—bile duct cancer	6.5e-05	6.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—bile duct cancer	6.17e-05	6.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—bile duct cancer	5.9e-05	5.9e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—bile duct cancer	5.84e-05	5.84e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNAS—bile duct cancer	5.83e-05	5.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—bile duct cancer	5.77e-05	5.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—bile duct cancer	5.65e-05	5.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—bile duct cancer	5.52e-05	5.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—bile duct cancer	5.28e-05	5.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	3.13e-05	3.13e-05	CbGpPWpGaD
